Scancell Holdings PLC represents a strong commitment to innovative cancer immunotherapies. The company's corporate philosophy revolves around developing novel, targeted immunotherapies to treat and prevent cancer. Scancell Holdings PLC focuses on leveraging its expertise in the field of ImmunoBody® and Moditope® platforms to create breakthrough treatments that harness the power of the immune system. With a dedicated team of scientists and researchers, Scancell is driven by a vision to improve patients' lives through effective and personalized cancer treatments. This UK-based biotechnology company is at the forefront of advancing immunotherapeutic solutions and is dedicated to making a positive impact in the fight against cancer.

Scancell Holdings PLC primarily operates in the United Kingdom.

Some significant milestones achieved by Scancell Holdings PLC include the successful development of their innovative ImmunoBody® and Moditope® platforms for cancer immunotherapy. The company has made notable progress in advancing its lead product, SCIB1, through clinical trials, demonstrating promising results in the treatment of melanoma patients. In addition, Scancell has achieved important collaborations and partnerships with renowned organizations, such as Cancer Research UK and the University of Nottingham, further validating their technologies. These achievements highlight Scancell Holdings PLC's dedication to advancing cancer treatment options and building strong industry alliances.

Scancell Holdings PLC is a renowned biotechnology company specializing in the development of novel immunotherapies for the treatment of cancer. Established in 1997, Scancell has pushed the boundaries of cancer research and developed innovative platforms such as ImmunoBody® and Moditope®. The company's cutting-edge technology stimulates the body's immune system to target and eliminate cancer cells selectively. Scancell's dedication to advancing cancer treatment has earned them recognition worldwide. With an experienced team of scientists and a strong commitment to innovation, Scancell Holdings PLC continues to be at the forefront of immunotherapy development, offering hope for improved cancer therapies in the future.

The main competitors of Scancell Holdings PLC in the market include pharmaceutical companies such as AstraZeneca, Bristol-Myers Squibb, and Merck & Co. These companies are also involved in developing innovative therapies and treatments for various diseases. As a leading player in the biotechnology sector, Scancell Holdings PLC faces competition in terms of research capabilities, product development, and market presence. However, Scancell Holdings PLC distinguishes itself with its unique immuno-oncology platform and promising pipeline. Its dedication to advancing immunotherapies places the company in a competitive position within the market.

Scancell Holdings PLC is primarily active in the biopharmaceutical industry.

The business model of Scancell Holdings PLC focuses on the development and commercialization of novel immunotherapies to treat cancer. The company utilizes its ImmunoBody® and Moditope® platforms to create innovative and effective treatment options. Scancell aims to leverage its expertise in immunology and cancer biology to develop therapies that activate the patient's immune system to specifically target and destroy cancer cells. By combining these platforms with cutting-edge technologies, Scancell is committed to advancing personalized medicine and improving patient outcomes in the field of oncology.

Scancell Holdings KGV ir -6,88.

Scancell Holdings KUV ir 0.

AlleAktien kvalitātes vērtējums Scancell Holdings ir 5/10.

Pašreiz nevar aprēķināt apgrozījumu Scancell Holdings.

gaidāmā Scancell Holdings peļņa ir -17,80 milj. GBP.

Scancell Holdings PLC is a biopharmaceutical company based in the UK that specializes in the development of cancer therapies and vaccines. The company was founded in 1997 and has since become one of the leading companies in this field.

Scancell Holdings izmaksā dividendes 0 GBP, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Scancell Holdings vai uzņēmums nedod dividendes.

Scancell Holdings ISIN ir GB00B63D3314.

Scancell Holdings WKN ir A1JZ3D.

Scancell Holdings simbols ir SCLP.L.

Pēdējo 12 mēnešu laikā Scancell Holdings maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Scancell Holdings plāno maksāt dividendes 0 GBP apmērā.

Scancell Holdings pašreizējā dividendu rentabilitāte ir .

Scancell Holdings maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Scancell Holdings pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 GBP. Tas atbilst dividendes ražībai 0 %.

Scancell Holdings tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Scancell Holdings apmērā 0 GBP, kas tika izmaksāta 27.09.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 27.09.2024..

Pēdējās dividendes izmaksa notika 27.09.2024..

Gadā 2023, Scancell Holdings izmaksāja 0 GBP dividendes.

Scancell Holdings dividendes tiek izmaksātas GBP.